Skip to content

Study · Not a test of the peptide alone · 1998

4 results

Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.

Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA

The Journal of clinical endocrinology and metabolism1 Apr 1998Cited by 52 (Europe PMC)

PMID9543138 (opens in a new tab)DOI10.1210/jcem.83.4.4711 (opens in a new tab)PepBankPUB-09543138
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Sermorelin aloneRandomized controlled trialMechanism

    In healthy men, a GHRH antagonist given before GHRP-6 reduced the maximal GH increase; no GHRH was given.

    In plain wordsIn healthy men, blocking the body's own GHRH removed most of the growth hormone rise caused by GHRP-6.

    Peptide
    Sermorelin
    Outcome
    DecreaseMaximal GH increase after GHRP-6 with GHRH antagonist
    Study

    n = 9

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Maximal GH increase
    33.8 microg/L
    saline then GHRP-6
    Maximal GH increase
    6.2 microg/L
    GHRH antagonist then GHRP-6

    Source sentences

    Summary
    GHRH-Ant eliminated most of the GH response to GHRP-6 [maximal increase over the baseline GH concentration, 33.8 +/- 4.8 vs. 6.2 +/- 1.8 microg/L (mean +/- SEM; P < 0.0001)
    2 context sentences
    Summary · context
    Nine healthy men between the ages of 20 and 30 yr were studied on two occasions.
    Summary · context
    They received either saline or GHRH-Ant (400 microg/kg, i.v.) at 0840 h, followed by GHRP-6 (1 microg/kg, i.v. bolus) at 0900 h.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02HumanNot a test of Sermorelin aloneRandomized controlled trialMechanism

    In healthy men, a GHRH antagonist given before GHRP-6 reduced the GH area under the curve; no GHRH was given.

    In plain wordsIn healthy men, blocking the body's own GHRH lowered the total growth hormone response to GHRP-6.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH area under the curve after GHRP-6 with GHRH antagonist
    Study

    n = 9

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH area under the curve
    1701 microg/min x L
    saline then GHRP-6
    GH area under the curve
    376 microg/min x L
    GHRH antagonist then GHRP-6

    Source sentences

    Summary
    area under the curve, 1701 +/- 278 vs. 376 +/- 113 microg/min x L (P < 0.001)].
    2 context sentences
    Summary · context
    Nine healthy men between the ages of 20 and 30 yr were studied on two occasions.
    Summary · context
    They received either saline or GHRH-Ant (400 microg/kg, i.v.) at 0840 h, followed by GHRP-6 (1 microg/kg, i.v. bolus) at 0900 h.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In nine healthy men, pre-treatment with the GHRH antagonist reduced the maximal GH increase after GHRP‑6 compared with saline pre-treatment (6.2 vs 33.8 microg/L).

    In plain wordsIn healthy men, blocking the body's own GHRH cut most of the growth hormone rise that GHRP‑6 caused, compared with saline.

    Peptide
    GHRP-6
    Outcome
    Not applicableMaximal GH increase over baseline after GHRP-6 with GHRH antagonist
    Study

    n = 9

    Comparator
    Saline before GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Maximal GH increase, saline then GHRP-6
    33.8 microg/L
    saline
    Maximal GH increase, GHRH-Ant then GHRP-6
    6.2 microg/L
    GHRH-Ant

    Source sentences

    Summary
    GHRH-Ant eliminated most of the GH response to GHRP-6 [maximal increase over the baseline GH concentration, 33.8 +/- 4.8 vs. 6.2 +/- 1.8 microg/L (mean +/- SEM; P < 0.0001
    2 context sentences
    Summary · context
    Nine healthy men between the ages of 20 and 30 yr were studied on two occasions.
    Summary · context
    They received either saline or GHRH-Ant (400 microg/kg, i.v.) at 0840 h, followed by GHRP-6 (1 microg/kg, i.v. bolus) at 0900 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In nine healthy men, pre-treatment with the GHRH antagonist reduced the GH area under the curve after GHRP‑6 compared with saline pre-treatment (376 vs 1701 microg/min x L).

    In plain wordsIn healthy men, blocking the body's own GHRH lowered the total growth hormone response to GHRP‑6, compared with saline.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH area under the curve after GHRP-6 with GHRH antagonist
    Study

    n = 9

    Comparator
    Saline before GHRP-6
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC, saline then GHRP-6
    1701 microg/min x L
    saline
    GH AUC, GHRH-Ant then GHRP-6
    376 microg/min x L
    GHRH-Ant

    Source sentences

    Summary
    area under the curve, 1701 +/- 278 vs. 376 +/- 113 microg/min x L (P < 0.001)
    2 context sentences
    Summary · context
    Nine healthy men between the ages of 20 and 30 yr were studied on two occasions.
    Summary · context
    They received either saline or GHRH-Ant (400 microg/kg, i.v.) at 0840 h, followed by GHRP-6 (1 microg/kg, i.v. bolus) at 0900 h.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 36Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 34 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.